Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$12.26 ▲ +0.14
(+1.16%)
MKT CAP: $2.68B • VOL: 3.23M
52W L $5 52W H $14
NEOG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-05-31 | FY 2024
FILED 2025-05-31 | FY 2023
FILED 2024-05-31 |
|---|---|---|---|
| Revenue (Total Sales) | $870.4M | $894.7M | $924.2M |
| YoY Revenue Growth % | -2.7% | -3.2% | — |
| Gross Profit | $408.5M | $421.4M | — |
| Gross Margin % | 46.9% | 47.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.6M | -$1.06B | $58.6M |
| Operating Margin % | -2.5% | -80.0% | 6.3% |
| Net Income (GAAP) | -$7.9M | -$1.09B | -$9.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $83.2M | $58.2M | $35.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $83.2M | $58.2M | $35.3M |
| FCF Margin % | 9.6% | 6.5% | 3.8% |
| Return on Invested Capital (ROIC %) | -0.6% | -24.5% | — |
| Cash & Short-Term Equivalents | $145.3M | $140.2M | — |
| Total Debt (Short + Long Term) | $792.9M | $889.9M | — |
| Total Stockholders' Equity | $2.10B | $2.67B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NEOG.